Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Spring on the Road
Spring Wellness
Premier Home Stylle Tour 2024
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Roivant Sciences Ltd
(NQ:
ROIV
)
12.23
+0.21 (+1.75%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Roivant Sciences Ltd
< Previous
1
2
3
4
5
6
7
Next >
Why Is Autoimmune Disease-Focused Immunovant Stock Trading Higher Today?
September 26, 2023
Immunovant Inc (NASDAQ: IMVT), a unit of Roivant Sciences Ltd (NASDAQ: ROIV), announced that subcutaneously administered doses of IMVT-1402 produced dose-dependent reductions in Immunoglobulin G (IgG)...
Via
Benzinga
These 2 Biotech Stocks Are Bucking a Down Market Tuesday
September 26, 2023
Stock index futures pointed to a lower open on Wall Street Tuesday morning.
Via
The Motley Fool
Roivant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results
September 26, 2023
From
Roivant Sciences
Via
GlobeNewswire
Analyst Expectations for Roivant Sciences's Future
September 18, 2023
Via
Benzinga
Roivant Announces Completion of Redemption of its Outstanding Warrants
September 11, 2023
From
Roivant Sciences
Via
GlobeNewswire
What 9 Analyst Ratings Have To Say About Roivant Sciences
August 31, 2023
Via
Benzinga
8 Analysts Have This to Say About Roivant Sciences
August 15, 2023
Via
Benzinga
Roivant Sciences: Is Vivek Ramaswamy’s Biotech Stock A Buy?
September 10, 2023
Roivant Sciences stock price has entered a major bull run as investors remain optimistic about the company’s future. The shares surged to a high of $12.67 on Friday, reaching its highest level since...
Via
Talk Markets
Vivek Ramaswamy's Parallels With Warren Buffett Run Deeper Than Wanting To Make Roivant The 'Berkshire Hathaway Of Drug Development'
September 04, 2023
Presidential hopeful Vivek Ramaswamy and Warren Buffett may share different political ideologies but they have at least a couple of things in common.
Via
Benzinga
2 Supercharged Growth Stocks Billionaires Can't Stop Buying
August 28, 2023
A top hedge fund has been steadily buying these two growth stocks in 2023.
Via
The Motley Fool
If You Invested $1000 In Vivek Ramaswamy-Founded Roivant When He Declared Presidential Bid, Here's How Much You'd Have Now
August 25, 2023
Roivant stock has outperformed the broader market and the biotech sector this year, mirroring the rise in the fortunes of its founder Vivek Ramaswamy.
Via
Benzinga
Roivant Announces Redemption Fair Market Value in Connection with Redemption of its Outstanding Warrants
August 17, 2023
From
Roivant Sciences
Via
GlobeNewswire
2 Magnificient Growth Stocks I'm Buying in August
August 02, 2023
These biotech stocks could markedly outperform the broader market.
Via
The Motley Fool
Roivant Sciences's Return on Invested Capital Insights
June 29, 2023
Via
Benzinga
Top Biotech Roivant, Formed By Vivek Ramaswamy, Reports Steep Losses, Light Sales
August 14, 2023
The company is working on a treatment for stomach diseases ulcerative colitis and Crohn's disease.
Via
Investor's Business Daily
Roivant Reports Financial Results for the First Quarter Ended June 30, 2023, and Provides Business Update
August 14, 2023
From
Roivant Sciences
Via
GlobeNewswire
3 Biotech Stocks That Analysts Are Drooling Over
August 07, 2023
With the medical science realm representing one of the most complex markets, these top analyst biotech picks can be worth your time.
Via
InvestorPlace
Roivant to Report Financial Results for the Quarter Ended June 30, 2023, and Provide Business Update on Monday, August 14, 2023
August 03, 2023
From
Roivant Sciences
Via
GlobeNewswire
Analyst Expectations for Roivant Sciences's Future
June 29, 2023
Via
Benzinga
Earnings Scheduled For August 14, 2023
August 14, 2023
Companies Reporting Before The Bell • Safe & Green Holdings (NASDAQ:SGBX) is likely to report quarterly loss at $0.23 per share on revenue of $6.88 million.
Via
Benzinga
Roivant Announces Redemption of Outstanding Warrants
August 02, 2023
From
Roivant Sciences
Via
GlobeNewswire
Vivek 'Da Vek' Ramaswamy: The 2024 Presidential Candidate Who Might Just Rap His Inauguration Speech
July 28, 2023
Donald Trump and Ron DeSantis have been the runaway favorites for the GOP nomination in the 2024 election, but there’s one candidate that has been climbing up the polls and gaining support from...
Via
Benzinga
Telavant, a Roivant Company, Advances Inflammatory Bowel Disease Program with First Patient Dosed in Global Phase 2 Trial of Novel Anti-TL1A Antibody RVT-3101 in Crohn’s Disease
July 27, 2023
From
Roivant Sciences
Via
GlobeNewswire
3 Biotech Stocks for Getting Rich in 2023
July 18, 2023
These 3 biotech stocks have seen stable or growing revenue this year. This makes them companies to keep on your watchlist.
Via
InvestorPlace
2 Nasdaq Stocks That Could Soar This Week
July 16, 2023
BridgeBio Pharma and Roivant Sciences could make big moves this week.
Via
The Motley Fool
Hollywood Wants To Use AI Replicas Of Actors, Major US Banks Deliver Q2 Earnings, Artificial Sweetener Aspartame Classified As 'Possible Carcinogen:' Today's Top Stories
July 14, 2023
Benzinga
Via
Benzinga
Roivant Surges As Roche Reportedly Considers $7 Billion Drug Takeover
July 14, 2023
The report sent Roivant Sciences higher Friday, but a deal is far from guaranteed.
Via
Investor's Business Daily
Republican Presidential Candidate Vivek Ramaswamy Founded Roivant In Discussions With Roche For $7B Stomach Disease(s) Drug Deal
July 14, 2023
Roivant Sciences Ltd (NASDAQ: ROIV), a biotech company founded by Vivek Ramaswamy, a Republican presidential candidate, is reportedly in discussions with Roche Holdings AG (OTC: RHHBY)
Via
Benzinga
Roivant Ranks No. 25 on Fast Company’s Fifth Annual List of the 100 Best Workplaces for Innovators and is the Winner on the Science and Technology List as a Part of the Best Workplaces for Innovators Program
July 11, 2023
Joining Adobe, Spotify, Nvidia, Morgan Stanley, and many others
From
Roivant Sciences
Via
GlobeNewswire
Schrödinger To Rally Around 14%? Here Are 10 Other Analyst Forecasts For Thursday
June 29, 2023
Keybanc boosted the price target for Micron Technology, Inc. (NASDAQ: MU) from $70 to $80. Keybanc analyst John Vinh maintained an Overweight rating. Micron shares rose 3.9% to $69.70 in pre-market...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.